Portopulmonary hypertension (PoPH) is diagnosed in 2-6% of liver transplantation (LT) candidates. We studied outcomes of candidates for LT suffering from PoPH. Data were collected retrospectively from a prospective registry. Pulmonary hemodynamic variables were collected at the time of PoPH diagnosis, at last evaluation before LT, and within 6 months and beyond 6 months after LT. Forty-nine patients (35 males, 48 6 8 years) were analyzed (median Model for End-Stage Liver Disease score 20). At baseline, mean pulmonary artery pressure (mPAP) was 44 6 10 mm Hg (range 26-73 mm Hg), cardiac index was 3.5 6 0.9 L/min/m 2 , and pulmonary vascular resistance was 5.6 6 2.8 Wood units. Hemodynamic reassessment performed in 35 patients who were treated with pulmonary arterial hypertension-targeted therapies before LT resulted in significant decreases in both mPAP (36 6 7 versus 47 6 10 mm Hg, P < 0.0001) and pulmonary vascular resistance (3.0 6 1.4 versus 6.1 6 3.1 Wood units, P < 0.0001). Fourteen patients (29%) died without having had access to LT. Thirty-five patients underwent LT and were followed up for a median of 38 months. Eight patients (23%) died after LT including 5 due to PoPH (after 1 day to 6 months). Among survivors (n 5 27), all patients treated with intravenous epoprostenol were weaned off post-LT, and endothelin receptor antagonist or phosphodiesterase type 5 inhibitors were continued in 15/27 patients (55%). At last evaluation, 20/27 patients (74%) had mPAP <35 mm Hg and 8 of them (30%) had mPAP <25 mm Hg. Overall survival estimates after LT were 80%, 77%, and 77% at 6 months, 1 year, and 3 years, respectively. Conclusion: Stabilization or reversibility of PoPH seems to be an attainable goal using the combination of pulmonary arterial hypertension-targeted therapies and LT in patients who are transplantation candidates. (HEPATOLOGY 2017;65:1683-1692. P ortopulmonary hypertension (PoPH) is a severe cardiopulmonary complication of portal hypertension that has a significant impact on functional status and survival of patients with liver disease.
, and pulmonary vascular resistance was 5.6 6 2.8 Wood units. Hemodynamic reassessment performed in 35 patients who were treated with pulmonary arterial hypertension-targeted therapies before LT resulted in significant decreases in both mPAP (36 6 7 versus 47 6 10 mm Hg, P < 0.0001) and pulmonary vascular resistance (3.0 6 1.4 versus 6.1 6 3.1 Wood units, P < 0.0001). Fourteen patients (29%) died without having had access to LT. Thirty-five patients underwent LT and were followed up for a median of 38 months. Eight patients (23%) died after LT including 5 due to PoPH (after 1 day to 6 months). Among survivors (n 5 27), all patients treated with intravenous epoprostenol were weaned off post-LT, and endothelin receptor antagonist or phosphodiesterase type 5 inhibitors were continued in 15/27 patients (55%). At last evaluation, 20/27 patients (74%) had mPAP <35 mm Hg and 8 of them (30%) had mPAP <25 mm Hg. Overall survival estimates after LT were 80%, 77%, and 77% at 6 months, 1 year, and 3 years, respectively. Conclusion: Stabilization or reversibility of PoPH seems to be an attainable goal using the combination of pulmonary arterial hypertension-targeted therapies and LT in patients who are transplantation candidates. (HEPATOLOGY 2017;65:1683-1692). P ortopulmonary hypertension (PoPH) is a severe cardiopulmonary complication of portal hypertension that has a significant impact on functional status and survival of patients with liver disease. (1, 2) PoPH belongs to the pulmonary arterial hypertension (PAH) group of the clinical classification of pulmonary hypertension. (3) Pulmonary vascular lesions in PAH are characterized by an intense proliferation of both pulmonary endothelial and vascular smooth muscle cells. (4) As in all forms of PAH, PoPH is characterized by a marked and sustained elevation of pulmonary vascular resistance (PVR), leading to an increase in pulmonary artery pressure, right ventricular failure (RVF), and ultimately death. (5) The occurrence of such a complication in patients who are candidates for liver transplantation (LT) may adversely impact their outcome. It has been shown that LT can precipitate postoperative RVF. The post-LT risk of pulmonary hypertension-related death is associated with high levels of pulmonary artery pressure (PAP) and PVR. Krowka et al. observed in a retrospective analysis that the risk of death due to RVF after LT was >50% when preoperative mean PAP (mPAP) was >35 mm Hg and PVR was >3 Wood units (WU). (6) For these reasons, PoPH is not an indication for LT and is usually considered a contraindication for this surgery, as opposed to hepatopulmonary syndrome. However, PAH-targeted therapies can be used in PoPH patients who are candidates for LT to decrease PAP and PVR and improve right ventricular function in order to facilitate a safer LT. (7) Despite recent progress in the management of patients with PoPH, longterm outcomes of PoPH patients who are candidates or who undergo LT remain unknown. Previous studies have been limited by the small numbers of enrolled patients, missing hemodynamic data, or lack of longterm follow-up. Some small case series have reported an improvement in PAH, sometimes a long time after LT. However, this was observed mainly in patients with mild pulmonary hypertension or patients with passive elevation of PAP due to very high cardiac output. (8) (9) (10) (11) (12) (13) (14) (15) The aim of this study was to report shortterm and long-term outcomes of a large cohort of patients with PoPH who are candidates for LT.
Patients and Methods

STUDY POPULATION
Data were analyzed from a total of 49 consecutive patients referred to the French reference center (Universit e Paris-Sud, Le Kremlin-Bicêtre, France) and two regional centers (Grenoble and Marseille) for evaluation of PAH between 1999 and 2013 and included in the French Pulmonary Hypertension Registry. According to French legislation, ethics committee agreement and provision of informed consent are not required for retrospective collection of data corresponding to current practice. However, the database was compiled anonymously according to the restrictive requirements of the Commission National Informatique et Libert es, the organization dedicated to privacy, information technology, and civil rights in France.
DIAGNOSIS OF CIRRHOSIS AND PORTAL HYPERTENSION
All patients included in the study were candidates for LT due to end-stage liver disease or hepatocellular carcinoma. The liver transplant center previously validated the indication for LT. All patients had cirrhosis documented by liver biopsy findings or typical clinical and/or biological signs and significant portal hypertension based on the hemodynamic measurement of a hepatic venous pressure gradient of >5 mm Hg or the presence of esophageal varices or of portal vein thrombosis. In There are no specific recommendations regarding the urgency for transplantation in those patients. The decision is made by an expert on an individual basis. (16) 
ARTICLE INFORMATION:
DIAGNOSIS AND ASSESSMENT OF PULMONARY HYPERTENSION
Patients evaluated for LT listing underwent systematic transthoracic echocardiography screening and were subsequently referred to a pulmonary hypertension center if pulmonary hypertension without any evidence for left heart disease was suspected. Precapillary pulmonary hypertension, defined by a resting mPAP of 25 mm Hg or more and a pulmonary artery wedge pressure of 15 mm Hg or less, was confirmed by right heart catheterization in all patients. We considered all patients with PVR of >2 WU. Patients were stratified according to hemodynamic criteria used to assess the post-LT mortality risk related to PoPH: low risk if mPAP <35 mm Hg and/or PVR <3 WU, intermediate risk if 35 mPAP < 50 mm Hg and PVR !3 WU, and high risk if mPAP !50 mm Hg. (6) In line with current guidelines, all patients with a diagnosis of PAH confirmed by right heart catheterization underwent extensive investigations in order to identify additional possible causes or risk factors for pulmonary hypertension. (4) Exclusion criteria were chronic thromboembolic pulmonary hypertension, pulmonary hypertension related to left heart diseases, pulmonary hypertension associated with significant lung diseases, and PAH associated with other conditions, including human immunodeficiency virus infection, congenital left-to-right shunts, connective tissue diseases, and exposure to anorectic drugs.
In addition to transthoracic echocardiography and right heart catheterization, baseline evaluation included physical examination, assessment of modified New York Heart Association functional class, routine blood tests, nonencouraged 6-minute walk test, pulmonary function tests, arterial blood gases, ventilation/perfusion lung scan, and high-resolution computed tomography.
TREATMENTS ADMINISTERED
All patients received nonspecific supportive therapies in accordance with current guidelines, i.e., diuretics to control signs and symptoms of RVF (including peripheral edema) and long-term oxygen therapy if hypoxemia was present.
(4) Anticoagulants were not usually given in those patients with severe liver disease and/or thrombocytopenia. The use of ß-adrenergic receptor blockers is usually associated with worsening of exercise capacity and pulmonary hemodynamics in patients with PoPH. (17) ß-Adrenergic receptor blockers were withdrawn in 3 patients from our series. Ligation of esophageal varices was performed in those patients. PAH-targeted medications, i.e., endothelin-receptor antagonists (ERA), phosphodiesterase type-5 (PDE-5) inhibitors, or prostanoids, were prescribed according to the choice of the treating physician. In the absence of formal recommendations for patients with PoPH, the choice of PAH-targeted therapy was based on several parameters including severity of PAH, severity of liver disease, and potential interactions with immunosuppressive therapy.
SUBSEQUENT ASSESSMENTS
Patients were reassessed for clinical, functional, and hemodynamic parameters every 3-6 months. In patients who underwent LT, subsequent reassessments were performed within 6 months and after a variable long-term period. We also determined the mortality rate on the LT waiting list, the number of patients who were removed from the waiting list because of persistent severe pulmonary hypertension, and the mortality rate after LT.
STATISTICAL ANALYSIS
Results are expressed as mean 6 standard deviation or median (interquartile range [IQR] 25-75). Baseline and postbaseline values for hemodynamic variables were compared using a two-sided paired t test if they were normally distributed and the nonparametric Friedman test otherwise. The chi-squared test was used to compare categorical variables. P < 0.05 was considered statistically significant. The Kaplan-Meier method was used to estimate survival at each time point. For the overall survival analysis after LT, we used the date of transplantation as the starting point to determine the survival duration. For the overall survival analysis after PoPH diagnosis, we used the first hemodynamic evaluation as the starting point to determine the survival duration. The cutoff date was December 15, 2015. Patients who were lost to follow-up were censored at the date of the last available visit.
Results
CHARACTERISTICS OF PATIENTS AT THE TIME OF DIAGNOSIS OF POPH
The study population comprised 49 consecutive patients with PoPH. Patient demographics and clinical and hemodynamic characteristics are shown in Table  1 . There was a majority of males (71%), and most patients displayed hemodynamic features of severe pulmonary hypertension. The majority of them had a high risk of death after LT according to the established hemodynamic criteria, i.e., mPAP of >50 mm Hg or PVR of >3 WU if mPAP was between 35 and 50 mm Hg (6) (Fig. 1) . Indication for LT was based on decompensated cirrhosis in 71% and hepatocellular carcinoma in 29%. Median MELD score at time of PoPH diagnosis was 20 (IQR 25-75, 16.5-23).
POPH MANAGEMENT AS A BRIDGE TO LT
Ten patients did not receive any PAH-targeted therapy before LT. They were exclusively managed with nonspecific supportive therapy, and ß-adrenergic receptor blocker therapy was withdrawn in 3 cases after esophageal varices ligation. For 1 of these patients, PoPH was diagnosed in the operating room at the time of LT. In these 10 patients, mPAP was 36 6 7 mm Hg, cardiac index was 3.4 6 0.6 L/min/m 2 , and PVR was 4.6 6 1.7 WU. Five of these patients had mPAP of <35 mm Hg and 5 mPAP of 35-50 mm Hg with PVR of more than 3 WU (Fig. 1) .
PAH-targeted therapy was prescribed as a bridge to LT in 39 patients including continuous intravenous epoprostenol infusion (n 5 19; median dose 16 ng Á kg 21 Á min
21
, range 12-22 ng Á kg 21 Á min 21 ) or a stable prostacyclin analogue (inhaled iloprost, n 5 1). Five patients were treated with an oral ERA (ambrisentan) and 21 with an oral PDE-5 inhibitor (sildenafil or tadalafil). Monotherapy was used in the majority of patients (n 5 29). Ten patients received sequential or initial combination therapy. A repeated clinical and hemodynamic assessment was performed after 5 months (IQR 25-75, 2.6-15) in 34 of these 39 patients. Five patients were not reassessed due to death in 2 and LT before reassessment in 3. Significant improvements from baseline were observed in hemodynamic variables (Table 2 ) with an increase in cardiac index and a decrease in PVR by a mean of 34% and 51%, respectively. Finally, the hemodynamic criteria allowing LT without excessive cardiovascular mortality (i.e., mPAP < 35 mm Hg or PVR <3 WU) were reached in 24/34 (70%).
OUTCOMES OF PATIENTS WHO DID NOT RECEIVE ANY PAH-TARGETED THERAPIES BEFORE LT
All 10 patients who did not receive any PAHtargeted therapies underwent LT. The median time on the waiting list of these patients was 2.2 months (IQR 25-75, 1.9-7.7). None of them received MELD exception points for PoPH. Figure 2A illustrates the course of hemodynamic variables after LT in those patients. Two patients died during the perioperative period: 1 died immediately after the surgical procedure from refractory RVF and 1 died at day 5 from hepatic complications. One patient did not have subsequent Abbreviation: SD, standard deviation.
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hemodynamic evaluation and was still alive 9 months after LT. Finally, a hemodynamic reassessment was performed in 7 patients within the 6 months following LT. In these patients, there was a trend toward increasing PVR (6.7 6 2.7 WU compared to 4.2 6 1.8 WU before LT, P 5 0.09). In 3 of these patients, a PAH-targeted medication (intravenous epoprostenol in 2 and dual oral combination therapy in 1) was initiated after hemodynamic reassessment. A final evaluation was performed after a median of 14.6 *Assessment was performed on waiting list for LT. Data for 6-minute walk distance and hemodynamics are given as mean 6 standard deviation.
months (IQR 25-75, 13.5-29.1) in these 7 patients ( Fig. 2A) . All displayed hemodynamic improvement. Six of them had mPAP <35 mm Hg and normal cardiac output at last evaluation. The 2 patients who had been treated with epoprostenol after LT were transitioned to an oral PDE-5 inhibitor.
OUTCOME OF PATIENTS WHO RECEIVED PAH-TARGETED THERAPY BEFORE LT
Eight out of 39 patients who received PAHtargeted therapies were ultimately not listed for LT due to insufficient hemodynamic response (n 5 6) or hepatocellular carcinoma progression (n 5 2) and subsequently died. Six additional patients died on the waiting list having met the hemodynamic criteria allowing LT (Fig. 1) . Causes of death were progression of liver disease in 3 patients, sepsis in 1, and unknown in the 2 remaining cases.
Finally, 25 out of the 39 patients (64%) who were treated with PAH-targeted medications underwent LT. The median time on the waiting list for these patients was 5.6 months (IQR 25-75, 2.3-8.3), and 6 of them received MELD exception points for PoPH. Four patients (16%) died from RVF at 7 days, 1 month, 2 months, and 6 months after LT. Two additional patients died from septicemia (n 5 1) and liver graft complication (n 5 1) within the first month following LT. Figure 2B illustrates the short-term and long-term hemodynamic outcome after LT. Eight out of the 19 survivors discontinued any PAH-targeted therapy at least 6 months after LT. At last evaluation, 11 patients were still treated with oral therapies, including a single patient who needed treatment escalation within the 3 months following LT. When epoprostenol was part of the PAH treatment (n 5 9), it was weaned off in all cases after a median time of 6.6 months (IQR 25-75, 5.1-12.1). At last evaluation (median 14 months, IQR 25-75, 11-35), 14/19 surviving patients (79%) had mPAP <35 mm Hg at rest with normalization of cardiac output. Six of them (32%) had normalization of resting pulmonary hemodynamic criteria (mPAP <25 mm Hg). No case of pulmonary hypertension worsening occurred after the 6 months following LT.
OVERALL SURVIVAL AFTER LT AND POPH DIAGNOSIS
The median follow-up time after LT was 38 months (IQR 25-75, 13-67). Overall survival estimates after LT were 80%, 77%, and 77% at 6 months, 1 year, and 3 years, respectively. Eight patients (23%) died during the period following LT including 5 due to PoPH (after 1 day, 7 days, 1 month, 2 months, and 6 months) (Fig. 3) .
The median follow-up after PoPH diagnosis was 42 months (IQR 25-75, 11-79). Overall survival estimates after PoPH diagnosis were 88%, 71%, and 57% at 6 months, 1 year, and 3 years, respectively (Fig. 4A) . Fourteen patients (29%) died without having had . The invasive hemodynamic evaluation showed an increase in PVR in the short term, necessitating initiation of targeted PAH therapies in 3 patients (dotted line). One patient died from acute right heart failure and 2 from liver complications (black dots). (B) Evolution of PVR in patients treated with PAHtargeted therapies before LT, at median 3.6 months (IQR 3-4.1) after LT (short-term evolution) and 14 months (IQR 11-35) after LT (long-term evolution). Four patients died from right heart failure within the 6 months following LT (7 days, 1 month, 2 months, and 6 months, respectively). access to LT. No significant difference in survival was observed between patients with mPAP <35 mm Hg and those with mPAP !35 mm Hg at baseline (Fig.  4B) .
Discussion
There is little information on the long-term outcome of patients with PoPH who are candidates for LT in the era of modern therapies for PAH. This study is the largest cohort of patients that analyzed the characteristics of these patients, their management, and long-term outcomes during the pre-LT and post-LT period. At the time of PoPH diagnosis, only 10 patients (20%) fulfilled hemodynamic criteria allowing a safe LT. In patients who did not fulfill these criteria, hemodynamic improvement with PAH-targeted therapies led to a substantially increased proportion of patients for whom LT became possible. Despite this optimal management, 14 patients (28%) died without undergoing LT. When LT was performed in patients with PoPH, we observed transitory worsening of pulmonary hypertension within the first 6 months following surgery. This worsening led to 5 pulmonary hypertension-related deaths, and transitory PAHtargeted treatment escalation was needed in 4 patients. After this period of instability, we always observed a major improvement in cardiopulmonary hemodynamics with stabilization, near-normalization, or normalization of mPAP and PVR in survivors. In all patients who received treatment with intravenous epoprostenol, it was possible to wean off the drug several months after LT.
The prevalence of PoPH in patients who are candidates for LT varies between 3% and 6%. (18, 19) According to the database of the French transplantation agency, 1,820 patients were listed in 2013 in France for LT. One may speculate that about 50-100 patients with PoPH per year should be listed for LT (indicated for liver disease). (20) The diagnosis of such a complication at the pre-LT evaluation has dramatic consequences for the patient. The risk of pulmonary hypertension-related death after LT is associated with   FIG. 3 . Overall survival estimates after LT were 80%, 77%, and 77% at 6 months, 1 year, and 3 years, respectively.
FIG. 4. (A)
Overall survival estimates after PoPH diagnosis were 88%, 71%, and 57% at 6 months, 1 year, and 3 years, respectively. (B) No significant difference in survival was observed between patients with mPAP <35 mm Hg and those with mPAP !35 mm Hg at baseline (P 5 0.5, log rank test). Abbreviation: NS, non significant. the level of both mPAP and PVR at the time of the surgical procedure. (6) Because the risk of death is not acceptable when mPAP is >45-50 mm Hg or when PVR level is >3 WU, these thresholds are considered contraindications for LT. The 2004 European Respiratory Society task force recommended that PoPH patients with severe hemodynamic impairments must be treated with PAH-targeted therapies to improve right ventricular function and decrease the risk of postoperative death.
(7) Some case reports and small studies have reported favorable outcomes after LT with the use of PAH-targeted therapies in patients with PoPH. (8) (9) (10) (11) (12) (13) (14) However, there is very little information about the management and the outcomes of these patients before, during, and after LT. In our study, we showed that patients with PoPH who are candidates for LT have a high mortality rate during the pre-LT period (29%). This underscores that PAH-targeted therapies have to be initiated as early as possible to rapidly improve hemodynamics and allow LT.
The choice of PAH-targeted therapies for PoPH is dependent on the severity of pulmonary hypertension, the importance of hepatic disturbances, and the urgency to perform LT. All classes of drugs (ERA, PDE-5 inhibitors, and prostanoids) have been used in patients with PoPH, (21) (22) (23) (24) (25) but no randomized controlled trial has ever been performed. In our study, all classes of drugs were used, with a high proportion of patients treated with intravenous epoprostenol. The potential risk of liver toxicity with ERAs limits their use in patients with PoPH, as well as the interaction of bosentan with immunosuppressive therapies. Ambrisentan or macitentan are preferable in patients with PoPH who are listed for LT. PDE-5 inhibitors do not have any liver toxicity and can be used safely in those patients. However, oral drugs may not be efficient enough in cases of severe pulmonary hypertension and/ or in those who need urgent LT. Intravenous epoprostenol should be considered in those situations. In our study, PAH-targeted therapies administered to patients awaiting LT led to a dramatic hemodynamic improvement in most cases, allowing LT to be performed when it was initially contraindicated due to PoPH. Finally, only 16% of patients with PoPH were not listed for LT due to insufficient hemodynamic improvement.
Six other patients died on the waiting list due to the combination of advanced liver disease and pulmonary hypertension. Because PoPH patients who have an indication for LT have worse survival, PoPH, like hepatopulmonary syndrome, justifies a priority access to transplantation using an expert component ("MELD exception") to reduce mortality rate on the waiting list. This system was introduced in 2006 in the United States and in 2007 in France. (26) No data are available on the impact of this graft allocation rule on pretransplantation and posttransplantation mortality in patients with PoPH.
After transplantation, the short-term postoperative period remains critical in PoPH patients, particularly in those who did not receive any preoperative PAHtargeted therapy. All deaths and PAH worsening needing treatment escalation occurred within the initial 6 months following LT, in particular during the immediate postoperative period. After hepatectomy and subsequent graft reperfusion, there are major hemodynamic changes that lead to marked increases in right ventricular preload. This can promote RVF and ultimately death in patients with preexisting pulmonary hypertension. Perioperative and postoperative monitoring with a pulmonary artery catheter is recommended to optimize right ventricular function and volume status in those patients. (27) (28) (29) (30) Cases of delayed pulmonary hypertension worsening have also been observed within 6 months after LT. The pathophysiological mechanisms of these late worsening cases are poorly understood. The release of cytokines by the graft after reperfusion may induce pulmonary endothelial dysfunction, promoting pulmonary vascular remodeling. (27, 29) Close clinical and hemodynamic monitoring is needed during the 6-month period post-LT, and PAH-targeted therapy must be reinforced in cases of hemodynamic worsening during this period.
The long-term outcome of PoPH after LT is important information from this study. After a 6-month period following LT, no cases of PoPH worsening were observed. The majority of patients had normalization or near-normalization of resting mPAP and PVR after LT, while PAH-targeted therapy was deescalated in most cases. Normalization of resting hemodynamics is exceptional in PAH as it is observed only in several cases of PAH associated with human immunodeficiency virus infection or systemic lupus erythematosus treated with a combination of disease-specific and PAH-targeted therapies. (31, 32) One could speculate that treating the "cause" of PoPH may lead to hemodynamic improvement. In that setting, PoPH could be an independent indication for LT irrespective of the severity of the underlying liver disease, as it is in hepatopulmonary syndrome.
We decided to include in the study 5 patients who had PVR between 2 and 3 WU, while PAH is currently defined by the guidelines as mPAP !25 mm Hg and PVR !3 WU. (4) We can justify this decision by the very interesting outcome of these patients after LT. One was treated before transplantation with epoprostenol because of mPAP >45 mm Hg with a favorable outcome after surgery. In contrast, 4 patients were transplanted without prior management of PoPH with PAH-targeted therapies. The first died from liver complications. Mean PAP and PVR remained >25 mm Hg and 2 WU, respectively, after LT in the second patient. Finally, we observed in the two remaining cases a dramatic increase in PVR at 7.5 and 8.7 WU within the 6 months following LT. These observations could suggest that a level of PVR >2 WU in patients with portal hypertension and a hyperdynamic profile could be the result of pulmonary vascular remodeling and not only the effect of "passive" elevation of pulmonary pressure.
The main limitations of this study are related to its retrospective nature and the long period of inclusion. The extent of missing data is limited by the requirement that preoperative and postoperative data of most patients be recorded in the French pulmonary hypertension registry. However, reliable data on perioperative hemodynamics were lacking in the study, introducing a potential limitation to survival analysis after LT. Moreover, the management and follow-up of patients from this study were very heterogeneous and therefore did not allow a determination of prognostic factors for success or failure. During the last 15 years, significant progress has been made in the management of PAH with the development of new targeted therapies that have also benefited patients suffering from PoPH. In addition, graft allocation rules have changed notably since 2007 with the addition of an expert component to the MELD score that allows priority access to LT for patients with PoPH or hepatopulmonary syndrome. A prospective study with standardized management of these patients would be needed to establish robust predictive criteria of success of LT in the management of patients with PoPH.
In conclusion, the management of patients with PoPH who are candidates for LT requires a multidisciplinary approach, in particular during the preoperative and the 6-month postoperative periods when the risk of PAH worsening is still elevated. After this period, stabilization, improvement, and normalization of pulmonary hemodynamics seem to be achievable goals by combining PAH-targeted medications and LT. Predictive factors for improvement of PoPH after LT need to be determined to better select patients who could benefit from this treatment approach, regardless of the severity of the underlying liver disease.
